Clinical Trial Details

Overview

Research Study Summary

A 17-week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment with LY2140023 Combined with SOC to placebo Combined with SOC as the Treatment of Patients with DSM-IV-TR Schizophrenia with Prominent Negative Symptoms

Purpose

The primary objective of this study is to determine if treatment with LY2140023 compared to placebo (an inactive substance), when added to a fixed dose of a standard of care (SOC) antipsychotic, will demonstrate significantly greater reduction of negative symptoms.

Patients included in this study will be concurrently receiving 1 of 4 current FDA approved antipsychotics: aripiprazole, olanzapine, risperidone, or quetiapine

Please contact Alexian Brothers for more information on participation.

To Learn more

CW ID: 176871
Date Last Changed: July 22, 2013

Clinical Trial Snapshot

Phase
2
Gender
Both Male and Female
Age
N/A
Overall Status
Recruiting
Duration
17 Weeks
Facility Type
N/A

Contact

Alexian Brothers Hospital Network
1786 Moon Lake Boulevard, Suite 200
Hoffman Estates, IL 60169
Phone: 847-230-3599

View Map

Research Center Information:

Alexian Brothers Hospital Network

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.